InvestorsHub Logo
Followers 1055
Posts 189434
Boards Moderated 1
Alias Born 06/19/2009

Re: None

Friday, 09/16/2016 4:11:11 PM

Friday, September 16, 2016 4:11:11 PM

Post# of 1121
GSK is a $105B Co. Results from a randomized, open-label, four-way, crossover study in 56 healthy volunteers showed a comparable safety profile between CaPre and GlaxoSmithKline's (GSK +1.1%) LOVAZA (omega-3-acid ethyl esters) capsules. In fasting subjects, CaPre showed better bioavailability than LOVAZA as measured by EPA and DHA levels.

ACST a perfect buyout imo. 10.7m O/S (cap is really a joke,only $20m)
http://seekingalpha.com/news/3208711-acasti-pharma-advances-high-triglyceride-fighter-capre-bridging-study-shows-similar-safety

investors took profits past 2 days after great results(this week) but forgot,cap is laughable.

My posts are my opinion and should not be used as investment advice. Make your own decisions in your stock trades.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ACST News